Knippschild U, et al. (1997) p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene 15, 1727-36 9349507

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S7-p - p53 (mouse) ▲

Modsite: _MTAMEEsQSDISLE SwissProt Entrez-Gene Orthologous residues p53 (human): P4‑p, p53 iso2 (human): P4‑p, p53 iso4 (human): ‑, p53 (mouse): S7‑p, p53 iso2 (mouse): S7‑p, p53 (rat): S4‑p, p53 (rabbit): S4‑p, p53 (green monkey): P4‑p Characterization Methods used to characterize site in vivo:  2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK1D (human) KINASE CK1E (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IC261 decrease

S9-p - p53 (mouse) ▲

Modsite: TAMEESQsDISLELP SwissProt Entrez-Gene Orthologous residues p53 (human): S6‑p, p53 iso2 (human): S6‑p, p53 iso4 (human): ‑, p53 (mouse): S9‑p, p53 iso2 (mouse): S9‑p, p53 (rat): S6‑p, p53 (rabbit): S6‑p, p53 (green monkey): S6‑p Characterization Methods used to characterize site in vivo:  2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK1E (human) KINASE CK1D (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IC261 decrease

S12-p - p53 (mouse) ▲

Modsite: EESQSDIsLELPLSQ SwissProt Entrez-Gene Orthologous residues p53 (human): S9‑p, p53 iso2 (human): S9‑p, p53 iso4 (human): ‑, p53 (mouse): S12‑p, p53 iso2 (mouse): S12‑p, p53 (rat): S9‑p, p53 (rabbit): S9‑p, p53 (green monkey): S9‑p Characterization Methods used to characterize site in vivo:  2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK1E (human) KINASE CK1D (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IC261 decrease